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Abstract 
Objective: The present study was designed to assess the effect of monthly ibandronate on 
health-related quality of life (HR-QoL) in patients with postmenopausal osteoporosis 
previously treated with weekly bisphosphonates. Methods: HR-QoL was assessed by Euroqol 
(EQ-5D) and Osteoporosis Targeted Quality of Life (OPTQoL) questionnaires. Results: The 
EQ-5D questionnaire showed significant improvement associated with ibandronate treatment 
occurring in mobility (p<0.01), usual activity (p<0.01), pain/discomfort (p<0.05) and 
anxiety/depression (p<0.05). In addition, ibandronate treatment considerably improved 
patients perceived health on a visual analogue scale (p<0.001). For the OPTQoL 
questionnaire patients reported less physical difficulty (p<0.001), fewer adaptations in their 
lives (p<0.001) and less fear (p<0.001), with ibandronate than with weekly bisphosphonates. 
Conclusion: the study demonstrated that patients who were transferred from weekly 
bisphosphonates to a monthly ibandronate experienced improved HR-QoL.  
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Introduction 
Health-related quality of life (HR-QoL) represents an important endpoint in the 
evaluation of patients with chronic diseases. Osteoporosis is a systemic bone disease that 
affects various aspects of a patient's life. A number of studies showed impaired QoL in 
patients with postmenopausal osteoporosis (1-4). These patients may be plagued by fear of 
fracture and consequent loss of independence which may lead to changes in psychosocial 
behaviour such as depression. Furthermore, low trauma fracture, the major consequence of 
osteoporosis, could be associated with chronic pain which considerably impairs  patient’s 
QoL.  
Over the last two decades bisphosphonates were considered the mainstay of treatment 
for postmenopausal osteoporosis. A substantial number of studies confirmed the effectiveness 
of various bisphosphonates on vertebral and proximal femur bone mineral density (BMD) 
gain, reduction of bone turnover markers and, finally, prevention of fracture (5-8). However, 
efficacy of treatment should not be evaluated only by BMD increase and fracture risk 
reduction but also by HR-QoL improvement. A majority of pivotal studies were inadequately 
designed to demonstrate the treatment effects on QoL. Nevertheless, some of them using 
different drugs available for the treatment of osteoporosis reported certain improvement in the 
patient's QoL (9-11).  
One of the major problems with bisphosphonate use is poor adherence to therapy. This 
is probably related to complicated dosing instructions and poor gastrointestinal tolerability 
which certainly have an impact on QoL. Several studies reported improved adherence with 
reducing bisphosphonate dosing frequency (12, 13). Moreover, data has shown that less 
frequent dosing is more convenient for the patient (14-16). 
Direct head-to-head studies investigating the effect of different bisphosphonates on 
fracture risk reduction are lacking. A few studies have compared their effect on bone markers 
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and BMD (17, 18). Conversely, similar studies of HR-QoL outcomes have not been 
performed. In view of this consideration, the present study was designed to assess the effect of 
monthly ibandronate on HR-QoL in patients with postmenopausal osteoporosis previously 
treated with weekly bisphosphonates. We hypothesized that these patients will experience 
certain improve of HR-QoL. 
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Materials and methods 
Study design 
This was a prospective, open-label, multi-centre study. Fourteen centres in Croatia 
were included. The study comprises two visits in a six month interval (visit window ±1 
month). At the baseline, patients were switched from weekly bisphosphonates to monthly 
ibandronate. There was no wash-out period between the two treatment regimens. QoL 
questionnaires were completed at baseline and at the end of the study. 
  
Patients 
The ITT populations comprised 395 patients with postmenopausal osteoporosis 
whereas 385 patients aged 66.6±8.1 years were available for the per-protocol analyses. 
Eligible were women who have been treated for osteoporosis with weekly alendronate or 
risedronate for at least six months prior to enrolment in the study. Excluded were patients 
receiving corticosteroids or any other drug that influences bone metabolism, had any disease 
that affects bone metabolism, had history of malignant disease or had any other disease that 
significantly impairs QoL such as significant upper gastrointestinal disease, active 
nephrolithiasis, severe osteoarthritis, rheumatoid arthritis, significant renal or liver disease, 
etc. Written informed consent was obtained by all participants. The study has been approved 
by The Local Ethics Committee.  
 
QoL questionnaires      
HR-QoL was assessed by Euroqol (EQ-5D) and Osteoporosis Targeted Quality of Life 
(OPTQoL) questionnaires.  
 EQ-5D is a two-part questionnaire comprising five questions that cover five 
dimensions of health: mobility, self-care, pain/discomfort, usual activity and 
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anxiety/depression (for each dimension there are three possible answers indicating no 
problems, some problems or severe problems) and self-related global valuation of perceived 
health using a visual analogue scale graded 0 to 100 (0= worst possible health; 100= perfect 
health) (19). 
The OPTQoL is a disease specific instrument designed to assess the impact of 
osteoporosis on a patient's QoL (20). It measures three different dimensions of health: 
physical difficulty, adjustments, and fears. The physical difficulty domain focuses on having 
difficulties performing certain activities. It contains 7 items that are rated on a 5-point Likert 
scale. The adjustments domain focuses on planning certain activities. It contains nine items 
which are rated on a 4-point Likert scale. The fears domain focuses on fears of sustaining pain 
or injuries while performing certain activities. It contains six items which are rated on a 4-
point Likert scale. The scores for each domain were converted to a 0 to 100 scale where 
higher scores indicate better quality of life. 
 
Statistical analysis 
All statistical analyses were
 
performed using STATISTICA (version 8.0).
 
Data are 
presented as median, minimum, maximum and interquartile range and proportions. Normal 
distribution and homogeneity of the variances
 
were tested using Lindman’s and Shapiro-
Wilk's W test. Differences between 2 points of measurements were analysed using ANOVA/ 
MANOVA for repeated measurements. Differences in the prevalence of individual conditions 
were measured using chi
2
 test. The level of significance of correlation between variables and 
the correlation trend were analyzed by the Pearson Correlation Test. Statistical significance 
was defined as a p value of 0.05 (p<0.05) in all analyses. 
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Results 
A total of 395 patients met the inclusion criteria and were enrolled in the study at 14 
study centres in Croatia. Of these 395 patients, complete data was available for 385 (97.5%). 
The other 10 (2.5%) patients withdrew from the study: 5 (1.3%) patients did not start monthly 
ibandronate according to the suggestion of their attending doctor, 4 (1.0%) patients had 
gastrointestinal adverse events and 1 (0.2%) patient was lost to follow up (Figure 1). No 
significant differences in any of the EQ-5D and OPTQoL domains at baseline were noted 
between the patients who completed the study and those who withdrew.   
  The proportion of patients reporting any problems in each of the five domains of EQ-
5D at both study visits are presented in Table 1. The greatest improvement associated with 
ibandronate treatment occurred on mobility (p<0.01) and usual activity (p<0.01), followed by 
pain/discomfort (p<0.05) and anxiety/depression (p<0.05). Conversely, for the item self-care, 
although ibandronate treatment prompted some improvement, the difference was not 
significant. In accordance with the above data, ibandronate treatment considerably improved 
patients perceived health on a visual analogue scale (median 70, IR 51-80 vs. median 70, IR 
60-80; p<0.001). 
 Figure 2 provides three OPTQoL subscale scores at baseline and 6 months after 
administration of ibandronate. Patients reported less physical difficulty (median 0.68, IR 0.50-
0.84 vs. median 0.61, IR 0.46-0.79; p<0.001), fewer adaptations in their lives (median 0.56, 
IR 0.50-0.64 vs. median 0.53, IR 0.44-0.64; p<0.001), and less fear (median 0.71, IR 0.50-
0.88 vs. median 0.63, IR 0.42-0.83; p<0.001), with ibandronate than with weekly 
bisphosphonates.   
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Discussion 
 Many comparative studies investigating the effect of different bisphosphonates on 
bone markers and bone mineral density have been carried out. The present study offers 
additional information regarding the impact of weekly and monthly bisphosphonates on HR-
QoL in patients with postmenopausal osteoporosis. Most recently,  few studies demonstrated 
patient’s preference for monthly ibandronate over weekly alendronate and risedronate (14-16, 
21) which is likely to influence therapeutic adherence and subsequently could have an impact 
on treatment efficacy. However, these studies did not address the issue of HR-QoL which is 
an important attribute of patient care.  
In our previous study exploring patient’s preference for different dosing regimens of 
bisphosphonate administration (14) a majority of the patients reported better QoL with 
monthly ibandronate than weekly bisphosphonates. Still, the study was not adequately 
designed to detect differences in QoL. 
Therefore, the main goal of the present study was to assess the effect of monthly 
ibandronate on HR-QoL in patients with postmenopausal osteoporosis previously treated with 
weekly bisphosphonates. For this purpose, two questionnaires, EQ-5D and OPTQoL, were 
used to analyse different dimensions of QoL. EQ-5D is a generic instrument whose main 
advantage is that its scores can be compared with other conditions. However, it does not 
precisely identify whether QoL changes are due to bisphosphonate treatment or some other 
condition. Therefore, the EQ-5D was combined with OPTQoL, a disease-targeted 
questionnaire that covers more specific aspects of osteoporosis. Our finding demonstrated that 
almost all aspects of HR-QoL measured by EQ-5D and OPTQoL were improved in the six 
months following a treatment with ibandronate compared with the baseline. We believe this is 
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the first report of better HR-QoL in patients with postmenopausal osteoporosis associated to 
one treatment over another.  
The basis behind the improved HR-QoL in patients receiving monthly ibandronate 
after previous treatment with weekly bisphosphonates remains to be clarified. Vertebral and 
non-vertebral fractures are major factors that affect patient’s QoL. The recent head-to-head 
database fracture study demonstrated significantly lower relative risk of vertebral fracture in 
patients receiving ibandronate than weekly bisphosphonates (22). However, the present study 
was not designed to asses the number and location of vertebral fractures either at baseline or 
at the end of the study. The relative risk reduction of vertebral fractures, at least in part, could 
be related to therapeutic adherence which has shown improvement with the reduced dosing 
frequency. Several studies reported superior patient’s adherence to monthly compared with 
weekly bisphosphonates (12, 13). 
 Another important issue is a chronic back pain related to vertebral fractures which is 
frequently one of the first symptoms of established osteoporosis. In the recent review on 
ibandronate and other bisphosphonates, the authors conclude that ibandronate offers an 
effective and convenient choice for the relief of bone pain in a variety of underlying bone 
diseases (23). Although this has been well proven in malignant conditions, similar data in 
osteoporosis is limited.  
Complicated bisphosphonate dosing instructions, specific time restrictions and 
gastrointestinal tolerability are important issues which could be related to compromised QoL 
in patients with postmenopausal osteoporosis. There is a strong evidence that monthly 
ibandronate is preferred by patients over weekly bisphosphonates (14-16, 21). Similarly, a 
majority of patients stated that a monthly dosing regimen is more convenient and better fitted 
to their lifestyle. Moreover, several studies reported significantly lower incidence of adverse 
events associated with monthly compared to weekly bisphosphonates (14, 24).       
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Though osteoporosis has a considerable effect on a variety of physical aspects of a 
patient’s life, the emotional dimensions of the disease, such as fear of falling and fear of 
changes in physical appearance, should not be underestimated. These patients are often 
anxious and worried which could result in depression (25). In the present study, significant 
difference in favour of ibandronate was observed in the anxiety/depression domain of EQ-5D 
and fear domain of OPTQoL.  
Potential limitations of the study involved lack of cross-over design as there was no 
control study group previously on monthly ibandronate switching to weekly bisphosphonates. 
Moreover, the study had an open-label design. However, this was inevitable as the study was 
set to reflect the situation we have in every day clinical practice. Another limitation of the 
study relates to the relatively short follow-up time (6 months).        
 To summarize, the present study demonstrated that patients who were transferred from 
weekly bisphosphonates to a monthly ibandronate experienced improved HR-QoL. We 
suggest this issue to be taken into account when considering treatment options. New studies 
using cross-over design are needed to further support our results.    
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